A randomized, double-blind, phase II study comparing the anti-retroviral safety and efficacy of dexelvucitabine (DFC) 200 mg once daily to lamivudine (3TC) 300 mg once daily in addition to optimized background therapy in HIV-1 infected subjects who have failed and/or harbor HIV with resistance mutations to NRTIs [nucleoside reverse transcriptase inhibitors], PIs [HIV protease inhibitors], and NNRTIs [non-nucleoside reverse transcriptase inhibitors].

Trial Profile

A randomized, double-blind, phase II study comparing the anti-retroviral safety and efficacy of dexelvucitabine (DFC) 200 mg once daily to lamivudine (3TC) 300 mg once daily in addition to optimized background therapy in HIV-1 infected subjects who have failed and/or harbor HIV with resistance mutations to NRTIs [nucleoside reverse transcriptase inhibitors], PIs [HIV protease inhibitors], and NNRTIs [non-nucleoside reverse transcriptase inhibitors].

Discontinued
Phase of Trial: Phase II

Latest Information Update: 03 Oct 2017

At a glance

  • Drugs Dexelvucitabine (Primary) ; Lamivudine
  • Indications HIV infections
  • Focus Therapeutic Use
  • Acronyms DECLARE 1
  • Sponsors Incyte Corporation
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 01 Jun 2012 Actual end date (Apr 2006) added as reported by ClinicalTrials.gov.
    • 11 Nov 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top